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Serotonin-2C receptors in the basolateral
nucleus of the amygdala mediate the anxiogenic
eﬀect of acute imipramine and ﬂuoxetine
administration
Maria Adrielle Vicente and Helio Zangrossi Jr.
Department of Pharmacology, School of Medicine of Ribeira˜o Preto, University of Sa˜o Paulo, Ribeira˜o Preto, SP, Brazil
Abstract
A growing body of evidence indicates that facilitation of serotonin-2C receptor (5-HT2CR)-mediated
neurotransmission in the basolateral nucleus of the amygdala (BLA) is involved in anxiety generation. We
investigated here whether BLA 5-HT2CRs exert a diﬀerential role in the regulation of defensive behaviours
related to generalized anxiety (inhibitory avoidance) and panic (escape) disorders. We also evaluated
whether activation of BLA 5-HT2CRs accounts for the anxiogenic eﬀect caused by acute systemic admin-
istration of the antidepressants imipramine and ﬂuoxetine. Male Wistar rats were tested in the elevated
T-maze after intra-BLA injection of the endogenous agonist 5-HT, the 5-HT2CR agonist MK-212 or the
5-HT2CR antagonist SB-242084. This test allows the measurement of inhibitory avoidance acquisition and
escape expression. We also investigated whether intra-BLA administration of SB-242084 interferes with
the acute anxiogenic eﬀect caused by imipramine and ﬂuoxetine in the Vogel conﬂict test, and imipramine
in the elevated T-maze. While intra-BLA administration of 5-HT and MK-212 facilitated inhibitory
avoidance acquisition, suggesting an anxiogenic eﬀect, SB-242084 had the opposite eﬀect. None of these
drugs aﬀected escape performance. Intra-BLA injection of a sub-eﬀective dose of SB-242084 fully blocked
the anxiogenic eﬀect caused either by the local microinjection of 5-HT or the systemic administration of
imipramine and ﬂuoxetine. Our ﬁndings indicate that 5-HT2CRs in BLA are selectively involved in the
regulation of defensive behaviours associated with generalized anxiety, but not panic. The results also
provide the ﬁrst direct evidence that activation of BLA 5-HT2CRs accounts for the short-term aversive
eﬀect of antidepressants.
Received 15 September 2010 ; Reviewed 3 November 2010 ; Revised 6 May 2011; Accepted 10 May 2011;
First published online 14 June 2011
Key words : Antidepressant, anxiety, basolateral amygdala, serotonin.
Introduction
The serotonin-2C receptor (5-HT2CR) plays an im-
portant role in emotional processing (Berg et al. 2008;
Giorgetti & Tecott, 2004 ; Landolt & Wehrle, 2009 ;
Millan, 2005). This receptor is a member of the family
of G-protein-coupled receptors and was ﬁrst identiﬁed
in the choroid plexus (Bockaert et al. 2010; Hoyer et al.
2002; Pazos et al. 1984). High levels of 5-HT2CR-
binding sites and 5-HT2CR mRNA are also observed in
the cortex and limbic areas such as the hippocampus,
amygdala and periaqueductal grey (Clemett et al.
2000; Mengod et al. 2010; Pompeiano et al. 1994).
Compelling evidence from clinical and animal
studies shows that facilitation of 5-HT2CR-mediated
neurotransmission increases anxiety. This has been
reported after the peripheral administration of both
non-selective 5-HT2CR agonists such as m-CPP and
TMFPP as well as of more selective, recently devel-
oped agonists such as MK-212 and RO 60-0175 (Bagdy
et al. 2001; Broocks et al. 1997; Jan et al. 2010; Kennett
et al. 1989; Overstreet et al. 2003; Setem et al. 1999;
Walker et al. 2005). On the other hand, treatment with
5-HT2CR antagonists such as ritanserin (non-selective)
or SB-242084 (selective) causes the opposite eﬀect
(Bressa et al. 1987; Ceulemans et al. 1985; Kennett et al.
1997; Martin et al. 2002). Clinical studies indicate that
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agomelatine, a melatonin receptor agonist and
5-HT2CR antagonist that has recently been marked as
an antidepressant, also has anxiolytic properties (de
Bodinat et al. 2010; Stein et al. 2008). In animal models,
the anxiolytic eﬀect of agomelatine has been mainly
attributed to its interaction with 5-HT2CRs (Millan et al.
2005).
The involvement of 5-HT2CRs in the genesis/
regulation of anxiety has also been revealed by genetic
approaches. It has been reported that whereas trans-
genic mice overexpressing 5-HT2CRs in the cerebral
cortex and diﬀerent limbic areas (e.g. amygdala,
hippocampus) show increased anxiety in the elevated
plus-maze (Kimura et al. 2009), 5-HT2CR knock-
out mice display an anxiolytic-like phenotype as
measured by diﬀerent experimental models (Heisler
et al. 2007).
Among the brain areas showing abundant distri-
bution of 5-HT2CRs, the amygdala has been seen as the
critical neuronal substrate for this receptor-mediated
eﬀect on anxiety. For instance, 5-HT2CR mRNA is
overexpressed in this area following a single session of
prolonged exposure to stressors, a procedure shown to
increase anxiety (Harada et al. 2008). Higher levels of
anxiety are also observed in rats after exposure to un-
avoidable tail-shocks, systemic injection of MK-212 or
repeated withdrawal from chronic ethanol diets, and
in all cases this eﬀect is fully blocked by the injection of
5-HT2CR antagonists such as SB-242084 into the baso-
lateral nucleus of the amygdala (BLA) (Christianson
et al. 2010; de Mello Cruz et al. 2005; Overstreet et al.
2006). The BLA has long been associated with anxiety
processing (Pesold & Treit, 1995, Rosen, 2004) and re-
ceives dense 5-HT innervation from the dorsal raphe
nucleus (Vertes, 1991).
It has also been proposed (Burghardt et al. 2007;
Millan, 2005) that activation of BLA 5-HT2CRs ac-
counts for the anxiogenic eﬀect found clinically during
the early stages of treatment with antidepressants such
as SSRIs (e.g. ﬂuoxetine, sertraline) or tricyclic com-
pounds (e.g. imipramine, clomipramine). While this
hypothesis has been put forward based on evidence
showing that systemic injection of 5-HT2CR antag-
onists fully counteracts the acute anxiogenesis caused
by antidepressants in diﬀerent animal models of
anxiety (Bagdy et al. 2001; Greenwood et al. 2008;
Yamauchi et al. 2004), no study has directly in-
vestigated this proposal by showing that intra-BLA
injection of 5-HT2CR antagonists exerts the same in-
hibitory eﬀect.
In the present study, we further addressed the role
played by BLA 5-HT2CRs in anxiety. More speciﬁcally,
we ﬁrst investigated whether this receptor exerts a
diﬀerential role in the regulation of defensive beha-
viours that have been related to diﬀerent subtypes of
clinically recognized anxiety. To this end, the eﬀect
caused by intra-BLAmicroinjection of the endogenous
agonist 5-HT, the selective 5-HT2CR agonist MK-212 or
the 5-HT2CR antagonist SB-242084 was investigated in
the elevated T-maze. This animal model, derived from
the elevated plus-maze, allows measurement, in the
same rat, of an anxiety- and a fear-related defensive
response, respectively, inhibitory avoidance and es-
cape (for a review of this test, see McNaughton &
Zangrossi, 2008 ; Pinheiro et al. 2007; Zangrossi &
Graeﬀ, 1997). Based on a series of pharmacological
studies (for a review see Blanchard et al. 2001; Graeﬀ &
Zangrossi, 2002 ; McNaughton & Gray, 2000), behav-
ioural inhibition responses such as inhibitory avoid-
ance have been linked with anxiety while escape has
been associated with fear. In terms of psychopath-
ology, these responses have been related to general-
ized anxiety and panic disorders, respectively
(Blanchard et al. 2001, 2003 ; Graeﬀ & Zangrossi, 2002;
Gray & McNaughton, 2000; McNaughton & Corr,
2004).
In a previous study from our group, we reported
that whereas a single systemic injection of imipramine
facilitated inhibitory avoidance acquisition in the el-
evated T-maze, indicating an anxiogenic eﬀect, a 21-d
treatment caused the opposite eﬀect. Chronic, but
not acute, treatment with imipramine inhibited
escape expression, suggesting a panicolytic-like eﬀect
(Teixeira et al. 2000). These results are in full agreement
with clinical evidence showing that the beneﬁcial ef-
fects of antidepressants on generalized anxiety and
panic disorders are only seen after prolonged admin-
istration (Bakker et al. 2005; Millan, 2005).
In a second experiment performed, we investigated
whether activation of 5-HT2CRs in the BLA accounts
for the acute anxiogenic eﬀect caused by imipramine
in the elevated T-maze inhibitory avoidance task. For
comparison, we veriﬁed whether these receptors were
also implicated in the acute imipramine and ﬂuoxetine
anxiogenic eﬀect detected in another generalized
anxiety-associated model, the Vogel conﬂict test (for
further details of this test see Graeﬀ & Zangrossi, 2002;
Millan & Brocco, 2003). Imipramine and ﬂuoxetine
were chosen as being the prototype drugs for the tri-
cyclic antidepressants and SSRIs, respectively. These
two classes of drugs are shown to be equally eﬀective
in treating depression and anxiety disorders such as
generalized anxiety and panic, even though the use
of the latter has supplanted the former due to its
better safety, tolerability and cost (Dupuy et al. 2011;
Ravindran & Stein, 2010).
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Methods
Animals
Male Wistar rats weighing 290–310 g were group-
housed (n=5 per group) under a 12-h light/dark cycle
(lights on 07:00 hours) at 22¡1 xC with free access to
food throughout the experiment, except during test-
ing. Water was also freely available, except in expts 2b
and 2c where periods of deprivation were followed
(see below). The experiments reported in this paper
were performed in compliance with the recom-
mendations of the SBNeC (Brazilian Society of
Neuroscience and Behaviour), which are based on the
US National Institutes of Health Guide for Care and
Use of Laboratory Animals.
Apparatus
The elevated T-maze was made of wood and had three
arms of equal dimensions (50r12 cm). One arm, en-
closed by 40-cm-high walls, was perpendicular to two
opposed open arms. To avoid falls, the open arms
were surrounded by a 1 cm high Plexiglas rim. The
whole apparatus was elevated 50 cm above the ﬂoor.
The open-ﬁeld test was performed in a wooden
square arena (60r60 cm), with 30-cm-high walls.
Luminosity at the level of the T-maze arms or open
ﬁeld was 60 lx.
The Vogel conﬂict test was performed as described
by Pelosi et al. (2009) in a Plexiglas box (length 42 cm,
width 25 cm, height 20 cm) with a stainless-steel grid
ﬂoor. A metallic spout of a drinking bottle containing
water projected into the box. The contact of the animal
with the spout and grid ﬂoor closed an electrical cir-
cuit controlled by a sensor (Insight Instruments,
Brazil), which produced 7 pulses/s whenever the ani-
mal was in contact with both components. Each pulse
was considered as a lick, and every 20 licks the animal
received a 0.5 mA shock for 2 s. The sensor recorded
the total number of licks and shocks delivered during
the test period. The apparatus was located inside a
sound-attenuated cage.
After each experimental session, the models were
cleaned with a 10% ethanol solution.
Drugs
The following drugs were used: 5-hydroxytryptamine
creatinine sulphate (5-HT; Sigma, USA), 6-chloro-
2-(1-piperazinyl)pyrazine hydrochloride (MK-212;
Tocris, USA), 6-chloro-2,3-dihydro-5-methyl-N-[6-
[(2-methyl-3-pyridinyl)oxy]-3-pyridinyl]-1H-indole-1-
carboxyamide dihydrochloride (SB-242084 ; Tocris),
imipramine hydrochloride (Sigma) and ﬂuoxetine
hydrochloride (EMS, Brazil). All drugs were dissolved
in sterile saline, except ﬂuoxetine, which was dis-
solved in a solution containing sterile saline with 2%
Tween-80.
Surgery
The animals were anaesthetized with 2,2,2-tribromo-
ethanol (250 mg/kg i.p.) and placed in a stereotaxic
frame. In all experiments, two guide cannulae made of
stainless steel (0.6 mm outer diameter, 0.4 mm inner
diameter) were bilaterally implanted in the brain
aimed at the BLA. The following coordinates from
bregma were used (Paxinos &Watson, 2007), BLA: AP
x2.5 mm, lateral ¡5.1 mm, ventral x6.2 mm. The
guide cannulae were ﬁxed to the skull with acrylic
resin and two stainless-steel screws. Stylets, the same
length as the guide cannulae, were introduced inside
them to prevent obstruction.
At the end of the surgery, all animals were injected
intramuscularly with 0.3 ml of antibiotic preparation
(benzylpenicillin and streptomycin, Pentabiotico
Veterina´rio Pequeno Porte, Brazil) to prevent possible
infections. In addition, ﬂuxinin meglumine (Schering–
Plough, Brazil ; 3 mg/kg), a drug with analgesic,
antipyretic and anti-inﬂammatory properties, was ad-
ministered subcutaneously for post-surgery analgesia.
The animals were left undisturbed for 5–7 d after
the surgery, except for normal handling during cage
cleaning.
Procedure
Elevated T-maze and open-ﬁeld tests
One day before the test, the rats were exposed to one
of the open arms of the T-maze for 30 min. A wooden
barrier mounted on the border between the central
area of the maze and the proximal end of the open arm
isolated this arm from the rest of the maze. It has been
shown that this pre-exposure to the open arm renders
the escape task more sensitive to the eﬀects of anti-
panic drugs, because it shortens the latencies of with-
drawal from the open arm during the test (Poltronieri
et al. 2003; Teixeira et al. 2000).
On the test day, in expt 1a, independent groups of
test-naive rats received an intra-BLA injection of MK-
212 (0, 0.01, 0.1 or 1 nmol ; n=8–9), 5-HT (0 or 16 nmol ;
n=10–11) or SB-242084 (0, 0.1, 1, 10 nmol ; n=7–9).
Ten minutes after the microinjections, the animals
were submitted to the behavioural tests.
In order to investigate if SB-242084 was able to block
the eﬀects of 5-HT, in expt 1b the animals were micro-
injected in the BLA with SB-242084 (0.01 nmol) or
saline, 5 min before microinjection of 5-HT (16 nmol)
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or saline. Thus, the following groups (n=6–7) were
formed: Sal/Sal, SB/Sal, Sal/5-HT and SB/5-HT. Ten
minutes after the last microinjection, the animals were
submitted to the behavioural tests.
In expt 2a, the animals were microinjected in the
BLA with SB-242084 (0.01 nmol) or saline, 10 min
before the systemic injection (i.p.) of imipramine
(10 mg/kg, 1 ml/kg) or saline. Thus, the following
groups (n=7–10) were formed: Sal/Sal, SB/Sal,
Sal/Imi and SB/Imi. The animals were tested in the
elevated T-maze and open-ﬁeld tests 30 min after
the systemic injections.
The test in the elevated T-maze was initiated by
inhibitory avoidance measurement. Each animal was
placed at the distal end of the enclosed arm of the el-
evated T-maze facing the intersection of the arms. The
time taken by the rat to leave this arm with the four
paws was recorded (baseline latency). The same
measurement was repeated in two subsequent trials
(avoidance 1 and 2) at 30-s intervals. Following avoid-
ance training (30 s), rats were placed at the end of the
same previously experienced open arm and the latency
to leave this arm with the four paws was recorded for
three consecutive times (escape 1, 2 and 3) with 30-s
inter-trial intervals. A cut-oﬀ time of 300 s was estab-
lished for the avoidance and escape latencies.
In order to assess possible drug eﬀects on locomotor
activity, immediately after testing in the elevated
T-maze, the total distance travelled by each rat in an
open ﬁeld was evaluated by a video-tracking system
(Ethovision, The Netherlands) for 5 min.
Vogel conﬂict test
Animals were water-deprived for 48 h prior to the test.
After the ﬁrst 24 h of deprivation, they were allowed
to drink freely for 3 min in the test cage in order to ﬁnd
the drinking bottle spout. Some animals that failed to
ﬁnd the spout were not included in the experiment.
Twenty-four hours later, animals were injected in
the BLA with SB-242084 (0.01 nmol) or saline, 10 min
before the systemic injection (i.p.) of imipramine
(10 mg/kg, 1 ml/kg) or saline (expt 2b, n=8–9) or
ﬂuoxetine (15 mg/kg, 1 ml/kg) or vehicle solution
(expt 2c, n=8–11). Thirty minutes later, they were re-
turned to the test cage. The test period lasted for 3 min,
and the animals received a 0.5-mA shock for 2 s
through the bottle spout every 20 licks.
In an independent group of non-operated rats
(n=4–6), we evaluated the eﬀect of a single in-
jection (i.p.) of imipramine (10 mg/kg) or ﬂuoxetine
(15 mg/kg) on water consumption. The procedure
adopted was the same used in the punished licking
test described above, except that the electric-shock
delivery system was inoperative.
The doses of the drugs were chosen on the basis
of previously published studies (Alves et al. 2004;
Christianson et al. 2010; Navailles et al. 2006; Teixeira
et al. 2000; Zanoveli et al. 2003).
For drug injection, needles (0.3 mm outer diameter)
were introduced through guide cannulae until their
tips were 2 mm below the end of the cannulae. The
drugs were microinjected in the BLA in a volume of
0.2 ml (for each side) over a period of 120 s using a 10 ml
microsyringe (Hamilton 701-RN, USA) attached to a
microinfusion pump (KD Scientiﬁc, USA). The dis-
placement of an air bubble inside the polyethylene
catheters connecting the syringe needles to the intra-
cerebral needles was used to monitor the micro-
injection. The intracerebral needles were removed 60 s
after the end of the injections.
Histology
After the experiments, animals were sacriﬁced under
deep urethane anaesthesia. The brain was perfused
intracardially with saline solution (0.9%) followed by
10% formalin solution before being removed and ﬁxed
in 10% formalin. Brain slices of 60 mm were made by
means of a microtome in order to localize the site of
the drug injection, according to the atlas of Paxinos &
Watson (2007).
Statistical analysis
Repeated-measures analysis of variance (ANOVA)
was used to analyse both avoidance and escape data.
In expt 1a, treatment (saline, MK-212, 5-HT, SB-
242084) was considered the independent factor and
trial (baseline, avoidance 1 and 2 latencies, escape 1, 2
and 3 latencies), the dependent, repeated measure. In
expt 1b, besides the dependent measure (trial), two
independent factors were considered: pre-treatment
with SB-242084 and treatment with 5-HT. In expt 2a,
the two independent factors were pre-treatment
with SB-242084 and treatment with imipramine.
Locomotion data in the open-ﬁeld were analysed by
one-way ANOVA (expt 1a) or two-way ANOVA
(expts 1b, 2a). The number of punished licks in the
Vogel conﬂict test was analysed by two-way ANOVA
(expts 2b, 2c). Multiple comparisons were performed
by Duncan’s post-hoc test.
Results
Figure 1 depicts the sites of drug injections into the
BLA of animals tested in the study.
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Expt 1a: MK-212 eﬀects
Figure 2a shows that MK-212 facilitated inhibitory
avoidance acquisition (treatment eﬀect : F3,31=3.31,
p<0.05), suggesting an anxiogenic eﬀect. Repeated-
measures ANOVA revealed a trial eﬀect (F2,62=33.95,
p<0.05), but not a trialrtreatment interaction. The
post-hoc test showed that MK-212 (0.01 and 0.1 nmol)
signiﬁcantly increased (p<0.05) avoidance 2 latency
compared to the saline group. This agonist did not
aﬀect escape performance (Fig. 2b) or locomotion in
the open ﬁeld (Table 1).
5-HT eﬀects
Figure 3a shows that, similarly to MK-212, 5-HT
facilitated inhibitory avoidance acquisition. There
were signiﬁcant eﬀects of treatment (F1,19=4.57,
p<0.05), trial (F2,38=18.96, p<0.05), and trialr
treatment interaction (F2,38=3.99, p<0.05). Student’s
t test revealed that 5-HT signiﬁcantly increased
(p<0.05) avoidance 2 latency. 5-HT did not aﬀect
escape expression (Fig. 3b) or locomotion in the open
ﬁeld (Table 1).
SB-242084 eﬀects
Figure 4a shows that SB-242084 impaired inhibitory
avoidance acquisition, indicating an anxiolytic eﬀect.
There was a signiﬁcant eﬀect of trial (F2,48=13.03,
p<0.05), and trialrtreatment interaction (F6,48=2.81,
p<0.05). The eﬀect of treatment was marginal for
statistical signiﬁcance (F3,24=2.71, p<0.07). SB-242084
at doses of 0.1 and 10 nmol signiﬁcantly decreased
(p<0.05) avoidance 2 latency compared to the saline
group. This antagonist did not aﬀect escape expression
(Fig. 4b) or locomotion in the open ﬁeld (Table 1).
Expt 1b: previous intra-BLA administration of
SB-242084 and 5-HT eﬀects
As illustrated in Fig. 5a intra-BLA injection of 5-HT
facilitated inhibitory avoidance acquisition. Previous
microinjection of SB-242084 counteracted this eﬀect.
Repeated-measures ANOVA showed signiﬁcant main
Bregma - 2.12
Bregma - 2.30
Bregma - 2.56
Bregma - 2.80
Fig. 1. Diagrammatic representation of coronal sections of
the rat brain showing the location of injection sites in the
basolateral nucleus of the amygdala ($). Figures represent
coordinates from the rat brain atlas of Paxinos & Watson
(2007), with respect to bregma. The number of points in the
ﬁgures is fewer than the total number of rats used because
of several overlaps.
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Fig. 2.MK-212 injection in the basolateral nucleus of the
amygdala facilitated (a) inhibitory avoidance acquisition,
without interfering with (b) escape expression in the elevated
T-maze (n=8–10). Values are mean¡S.E.M. * p<0.05
compared to the saline-injected group.
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eﬀects of trial (F2,46=33.40, p<0.05) and treatment
with the agonist (F1,23=9.00, p<0.05). There was also
a signiﬁcant interaction among the three factors
analysed (agonistrantagonistrtrial : F2,46=7.12,
p<0.05). The post-hoc test showed that 5-HT signiﬁ-
cantly increased (p<0.05) avoidance 1 and 2 latencies.
Prior intra-BLA administration of SB-242084 fully
blocked this anxiogenic eﬀect.
None of the treatments employed altered escape
expression (Fig. 5b) or locomotion in the open ﬁeld
(Table 1).
Expt 2a: previous intra-BLA administration of
SB-242084 and systemic imipramine eﬀect in the
elevated T-maze
Figure 6a shows that imipramine signiﬁcantly
facilitated inhibitory avoidance acquisition and that
this anxiogenic eﬀect was blocked by prior intra-BLA
administration of SB-242084. Repeated-measures
ANOVA showed signiﬁcant main eﬀects of trial
(F2,60=37.21, p<0.05) and antagonist treatment
(F1,30=10.09, p<0.05). There was also a signiﬁcant in-
teraction among the three factors analysed (systemic
drugrantagonistrtrial : F2,60=3.42, p<0.05). The
post-hoc test showed that imipramine signiﬁcantly in-
creased (p<0.05) avoidance 1 and 2 latencies. Prior
intra-BLA administration of SB-242084 fully blocked
this anxiogenic eﬀect.
None of the treatments employed altered escape
expression (Fig. 6b) or locomotion in the open ﬁeld
(Table 1).
Expt 2b: previous intra-BLA administration of
SB-242084 and systemic imipramine eﬀect in the
Vogel conﬂict test
Figure 7 shows that imipramine signiﬁcantly de-
creased the number of punished licks in the Vogel
conﬂict test and that this anxiogenic eﬀect was counter-
acted by previous microinjection of SB-242084. Two-
way ANOVA showed a signiﬁcant eﬀect of treatment
with the antagonist (F1,33=4.65, p<0.05) and a mar-
ginal eﬀect of the systemic treatment (F1,33=3.70,
p=0.06). There was also a signiﬁcant interaction
Table 1. Eﬀect of treatment with intra-BLA or systemic
injection of drugs on the distance travelled in the open-ﬁeld
test
Treatment (nmol) Distance travelled (m)
Expt 1a
Saline 21.87¡1.51
MK-212 (0.01) 21.00¡1.69
MK-212 (0.1) 21.35¡1.11
MK-212 (1) 26.66¡1.92
Saline 27.87¡3.22
5-HT (16) 23.53¡1.40
Saline 24.57¡3.34
SB-242084 (0.1) 28.89¡4.16
SB-242084 (1) 32.28¡4.83
SB-242084 (10) 22.13¡3.85
Expt 1b
Saline/saline 24.50¡1.78
SB-242084/saline 23.56¡2.01
Saline/5-HT 22.27¡2.36
SB-242084/5-HT 23.96¡1.82
Expt 2a
Saline/saline 24.07¡1.74
SB-242084/saline 22.31¡1.72
Saline/imipramine 25.36¡1.24
SB-242084/imipramine 22.71¡1.29
Values are mean¡S.E.M.
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Fig. 3. 5-HT injection (16 nmol) in the basolateral nucleus of
the amygdala facilitated (a) inhibitory avoidance acquisition
without interfering with (b) escape expression in the elevated
T-maze (n=10–11). Values are mean¡S.E.M. * p<0.05
compared to the saline-injected group.
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between the two factors (systemic drugrantagonist :
F1,33=10.5, p<0.05).
Expt 2c : previous intra-BLA administration of
SB-242084 and systemic ﬂuoxetine eﬀect in the
Vogel conﬂict test
As observed with imipramine, ﬂuoxetine also de-
creased the number of punished licks in the Vogel
conﬂict test and this anxiogenic eﬀect was blocked by
previous microinjection of SB-242084 (see Fig. 8). Two-
way ANOVA showed a signiﬁcant eﬀect of treatment
with the antagonist (F1,34=21.85, p<0.05) and the sys-
temic injection of ﬂuoxetine (F1,34=4.12, p<0.05).
There was also a signiﬁcant interaction between the
two factors (systemic drugrantagonist : F1,34=5.14,
p<0.05).
As revealed by the additional control experiment
performed (values are mean¡S.E.M.), neither imipra-
mine (Sal=1136.7¡64.7, Imi=1152.7¡62.9) nor
ﬂuoxetine (vehicle=1169.3¡68.6, Flx=1200.2¡79.7)
aﬀected the number of unpunished licks on the test
day.
Discussion
The objective of the present study was to investigate
the role played by 5-HT2CRs of the BLA in the regu-
lation of anxiety- and panic-related defensive behav-
iours and their involvement in the mediation of the
acute anxiogenic eﬀect caused by the antidepressant
drugs imipramine and ﬂuoxetine.
The results showed that intra-BLA injection of the
5-HT2CR agonist MK-212 or the endogenous agonist
5-HT facilitated inhibitory avoidance acquisition,
suggesting an anxiogenic eﬀect, without aﬀecting es-
cape performance. On the other hand, microinjection
of the selective 5-HT2CR antagonist SB-242084 caused
the opposite eﬀect, i.e. anxiolysis, also without chang-
ing escape expression. The rise in anxiety observed
after 5-HT microinjection was fully blocked by pre-
vious intra-BLA injection of SB-242084, conﬁrming the
recruitment of 5-HT2CR for this eﬀect.
Regarding the results of MK-212, it is of note that
the highest dose tested did not share the anxiogenic
eﬀect observed with lower doses. This lack of eﬀect
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Fig. 4. Intra-basolateral nucleus of the amygdala injection
of SB-242084 impaired (a) inhibitory avoidance acquisition
without aﬀecting (b) escape expression in the elevated
T-maze (n=6–8). Values are mean¡S.E.M. * p<0.05 compared
to the saline-injected group.
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Fig. 5. Intra-basolateral nucleus of the amygdala
administration of SB-242084 (0.01 nmol) blocked the
facilitatory eﬀect on (a) inhibitory avoidance acquisition
caused by local microinjection of 5-HT (16 nmol) (n=6–7).
(b) Lack of SB-242084 and 5-HT eﬀect on escape performance
(n=6–7). Values are mean¡S.E.M. + p<0.05 compared to all
other groups.
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may conceivably reﬂect the interaction of this drug
with other sites besides 5-HT2CRs. Although MK-212
displays high aﬃnity for 5-HT2CRs it also binds with
moderate aﬃnity to 5-HT2ARs (Knight et al. 2004).
It has been shown in our laboratory that intra-BLA
administration of the preferential 5-HT2AR agonist
DOI causes anxiolysis in the elevated T-maze
(C. A. Strauss, M. A. Vicente, H. Zangrossi Jr., un-
published results). It is therefore possible that inter-
action of MK-212 with 5-HT2Rs, that exert an opposed
role in anxiety modulation, may have contributed to
the lack of eﬀect observed with the highest dose.
None of the compounds tested in the present study
interfered with the distance travelled in the open ﬁeld,
thereby excluding non-speciﬁc motor interference as
the main factor accounting for the eﬀects observed
upon inhibitory avoidance acquisition.
Taken together these results are indicative that
5-HT2CRs in the BLA are selectively involved in the
regulation of defensive behaviours associated with
generalized anxiety (inhibitory avoidance), but not
panic (escape).
The facilitatory role of BLA 5-HT2CRs in anxiety has
also been demonstrated in other experimental models.
Campbell & Merchant (2003) reported that bilateral
injection of m-CPP or IL-639, non-selective and selec-
tive 5-HT2CR agonists, respectively, had anxiogenic
consequences in the ultrasonic vocalization and
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Fig. 6. Intra-basolateral nucleus of the amygdala
administration of SB-242084 (0.01 nmol) blocked the
facilitatory eﬀect on (a) inhibitory avoidance acquisition
caused by an acute systemic injection of imipramine
(10 mg/kg) (n=7–10). (b) Lack of SB-242084 eﬀect on the anti-
escape consequence of imipramine administration (n=7–10).
Values are mean¡S.E.M. * p<0.05 compared to all other
groups.
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Fig. 7. Intra-basolateral nucleus of the amygdala
administration of SB-242084 (0.01 nmol) blocked the decrease
in the number of punished drinking caused by an acute
systemic injection of imipramine (10 mg/kg) (n=8–9). Values
are mean¡S.E.M. + p<0.05 compared to all other groups.
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Fig. 8. Intra-basolateral nucleus of the amygdala
administration of SB-242084 (0.01 nmol) blocked the decrease
in the number of punished drinking caused by an acute
systemic injection of ﬂuoxetine (15 mg/kg) (n=8–11). Values
are mean¡S.E.M. + p<0.05 compared to all other groups.
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open-ﬁeld tests. This eﬀect was blocked by the sys-
temic injection of SB-242084. In the elevated plus-
maze, systemic injection of MK-212 increased anxiety
and intra-BLA injection of the non-selective 5-HT2CR
antagonist ritanserin counteracted this eﬀect (de Mello
Cruz et al. 2005).
The ﬁnding that SB-242084 has an anxiolytic eﬀect
when injected in the BLA raises two, possibly concur-
rent, interpretations : one is that 5-HT in this nucleus
exerts a tonic facilitatory inﬂuence on anxiety-related
behaviours (i.e. 5-HT is continuously released in the
area) and the other is that BLA 5-HT2CRs are spon-
taneously active (constitutively active) in the regu-
lation of these behaviours. Regarding the latter, a
wealth of evidence indicates that 5-HT2CRs possess
high levels of constitutive activity, i.e. they can activate
intracellular signalling without the presence of the
endogenous agonist (for a review see Aloyo et al.
2009). If this is the case in the present study, SB-242084
could be acting as an inverse agonist, a mode of action
already reported for this drug (Aloyo et al. 2009).
Further studies assessing, for instance, the behavioural
eﬀect of intra-BLA injection of SB-242084 in the brain
of 5-HT-depleted animals (e.g. by intra-dorsal raphe
nucleus injection of the neurotoxin 5,7-dihydroxy-
tryptamine), will certainly contribute to the clariﬁ-
cation of this question.
The eﬀect of 5-HT2CR activation in the BLA in
the elevated T-maze was opposite to that caused
by the stimulation of 5-HT1ARs in this subnucleus. In
test-naive rats, bilateral microinjection of 8-OH-DPAT,
a 5-HT1AR agonist, or the benzodiazepine anxiolytic
midazolam impaired inhibitory avoidance acquisition,
without changing escape expression (Zangrossi et al.
1999). More recently, we observed that in animals
previously exposed to one of the elevated T-maze
open arms, as performed in the present study, intra-
BLA injection of 8-OH-DPAT retained its anxiolytic
eﬀect, but also inhibited escape expression, indicating
a panicolytic-like eﬀect (C. A. Strauss, M. A. Vicente,
H. Zangrossi Jr., unpublished results). As mentioned
before, the same pattern of results was observed
after the intra-BLA injection of the preferential
5-HT2AR agonist DOI (C. A. Strauss, M. A. Vicente,
H. Zangrossi Jr., unpublished results). Therefore,
among those 5-HT receptor subtypes more consist-
ently implicated in defence regulation, 5-HT2CRs in
the BLA seem to be unique in their selective involve-
ment with anxiety- but not panic-related behaviours.
The most important ﬁnding of this study is that
intra-BLA administration of a sub-eﬀective dose of
SB-242084 fully blocked the acute anxiogenic eﬀect
caused by imipramine and ﬂuoxetine in the Vogel
conﬂict test and imipramine in the elevated T-maze.
This observation adds to a series of evidence showing
that 5-HT2CR in the BLAmediates the anxiogenic eﬀect
generated by diﬀerent conditions/situations such as
exposure to stressful stimuli (Christianson et al. 2010)
and discontinuation of chronic ethanol ingestion
(Overstreet et al. 2006). It also extends previous
evidence showing that systemic injection of 5-HT2CR
antagonists fully counteracted the acute anxiogenesis
caused by antidepressants in diﬀerent animal models
of anxiety (Bagdy et al. 2001; Burghardt et al. 2007;
Greenwood et al. 2008; Yamauchi et al. 2004).
Although no study has directly investigated the ef-
fect of imipramine or ﬂuoxetine, in-vivo microdialysis
studies have shown that acute systemic injection of the
SSRI citalopram enhances 5-HT levels in the amygdala
(Bosker et al. 2001; Gobert et al. 2009). The same eﬀect
on 5-HT concentration was observed when the SSRI
ﬂuvoxamine was injected directly into the BLA (van
der Stelt et al. 2005). In keeping with the present result
with 5-HT, intra-BLA microinjection of ﬂuoxetine
enhanced anxiety in a contextual fear paradigm
(Martinez et al. 2007). Therefore, it is conceivable that
facilitation of 5-HT neurotransmission in the BLA,
through mediation of 5-HT2CRs, may account for the
acute anxiogenic eﬀect caused by diﬀerent classes of
antidepressants known to interfere with the extra-
cellular availability of 5-HT. In the case of imipramine
and ﬂuoxetine, evidence in the literature shows
that these antidepressants may interact directly with
5-HT2CRs, although with weak aﬃnity (Ni & Miledi,
1997 ; Pa¨lvima¨ki et al. 1996). However, given evidence
that these drugs exert antagonistic and not agonistic
activity on these receptors (Ni & Miledi, 1997 ;
Pa¨lvima¨ki et al. 1996) and that injection of SB-242084 in
the BLA is anxiolytic (expt 1a), it is unlikely that this
mechanism of action mediates their acute anxiogenic
eﬀect.
We are currently investigating whether prolonged
treatment with imipramine or ﬂuoxetine aﬀects the
reactivity of 5-HT2CRs in the BLA. According to
Millan (2003, 2005), the shift from anxiogenesis to
anxiolysis caused by these drugs over time involves
both the desensitization of 5-HT2CRs and the sensiti-
zation of 5-HT1ARs located in limbic areas. In line with
this hypothesis, as mentioned above, facilitation of
5-HT1AR-mediated neurotransmission in the BLA is
anxiolytic in the elevated T-maze (Zangrossi et al.
1999). It also remains to be investigated whether this
eﬀect is potentiated after chronic treatment with anti-
depressants.
In conclusion, our ﬁndings highlight the selective
involvement of BLA 5-HT2CRs in the regulation of
5-HT2CRs and anxiogenic eﬀect of antidepressants 397
anxiety-related behaviours and provide the ﬁrst direct
evidence of their role in mediation of the short-term
aversive eﬀect of antidepressants.
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